Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis | Zendy

Kaikai Shen | Zendy; Jinggang Cui | Zendy; Yuqing Wei | Zendy; Xiaojun Chen | Zendy; Guo-Hua Liu | Zendy; Xiaolai Gao | Zendy; Wei Li | Zendy; Huiling Lü | Zendy; Ping Zhan | Zendy; Tangfeng Lv | Zendy; Lin Dang | Zendy

Open Access

Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis

Author(s) -

Kaikai Shen,

Jinggang Cui,

Yuqing Wei,

Xiaojun Chen,

Guo-Hua Liu,

Xiaolai Gao,

Wei Li,

Huiling Lü,

Ping Zhan,

Tangfeng Lv,

Lin Dang

Publication year - 2018

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2018.11.72

Subject(s) - medicine , lung cancer , hazard ratio , oncology , subgroup analysis , confidence interval , odds ratio , meta analysis , adverse effect , combination therapy , chemotherapy

Immune checkpoint inhibitors (ICIs) combined with chemotherapy have been applied as a first-line treatment for lung cancer, but consistent beneficial results have not been documented. Therefore, our meta-analysis aimed to evaluate the effectiveness and safety of combination therapy to promote its application.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research